ESMO 2025 | DNA immunotherapy (INO-3107) in HPV-6 & 11 recurrent respiratory papillomatosis: long-term efficacy
Nabil Saba, MD, Emory University, Atlanta, GA, discusses the challenges of managing recurrent respiratory papillomatosis, a rare disease caused by HPV-6 and 11, and highlights the potential of DNA-based therapies, such as INO-3107, in reducing the need for surgical interventions and inducing an immune mechanism to prevent tumor recurrences. Dr Saba notes that the treatment has shown promising results, with a significant decline in surgical interventions required by patients, reaching up to 80% in the second year, and emphasizes the importance of understanding the immune-based mechanisms underlying this virally mediated condition. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
